Tofacitinib in ulcerative colitis

Thomas P Archer, Gordon W Moran, Subrata Ghosh

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Cytokines orchestrate immune and inflammatory responses involved in the pathogenesis of ulcerative colitis (UC). Protein kinases are essential for signal transduction in eukaryotic cells. Janus kinases (JAKs) are a family of protein tyrosine kinases that play a pivotal role in cytokine receptor signaling. Indeed, a major subgroup of cytokines use Type I and II cytokine receptors which signal via the activation of JAKs. Tofacitinib is an oral JAK inhibitor that has been studied in autoimmune pathologies, including UC and rheumatoid arthritis with good overall efficacy and acceptable safety profile. This literature review was performed with the goal of summarizing the knowledge on JAK inhibitors in UC treatment.

Original languageEnglish
Pages (from-to)495-502
Number of pages8
Issue number5
Publication statusPublished - May 2016
Externally publishedYes


  • Animals
  • Arthritis, Rheumatoid
  • Autoimmunity
  • Colitis, Ulcerative
  • Cytokines
  • Humans
  • Janus Kinases
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • Signal Transduction
  • Journal Article
  • Review


Dive into the research topics of 'Tofacitinib in ulcerative colitis'. Together they form a unique fingerprint.

Cite this